Details:
Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to comarket an innovative drug, Rytstat (desidustat), first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease, in India.
Lead Product(s): Desidustat
Therapeutic Area: Hematology Product Name: Rytstat
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 30, 2023
Details:
Orofer (ferric carboxymaltose) which is capable of releasing iron, helping in the synthesis of haemoglobin and increases red blood cell count. As a result, it treats iron deficiency anaemia.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Orofer
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Oxemia (desidustat), a HIF-PF inhibitor met its primary endpoints for haemoglobin improvement in DREAM-D and DREAM-ND Phase III clinical trials and showed good safety profile, downregulation of hepcidin, improved iron mobilization and LDL-C reduction in CKD patients.
Lead Product(s): Desidustat
Therapeutic Area: Hematology Product Name: Oxemia
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
Details:
Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application for Argatroban injection, 50 mg/50 ml (1 mg/ml), single-dose vial presentation, it said in a filing to BSE.
Lead Product(s): Argatroban
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2021
Details:
Cipla has acquired the four brands namely CPink, CDense, Productiv and Folinine to further strengthen its presence in the women's health segment, Cipla said in a filing to the BSE.
Lead Product(s): Folic Acid,Iron
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cipla
Deal Size: $12.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition February 07, 2020